StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Could be us soon... OCX up 60%

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Mar 16, 2023 5:17pm

89 Views

Post# 35343622

RE:Could be us soon... OCX up 60%

Look at the financials for both ocx and stage.

OCX annual revenues of $7 million gross profit of 0.19 million and has a market cap of $35 million

Stage annual revenues of $5 million gross profit of 1.19 million. Valued at $11 million market cap.

Based on ocx valuation stage should be $25 million or $0.25 share price. Very undervalued and once Tripp starts showing revenue growth this should climb well over $0.25

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale